Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03703154 · ClinicalTrials.gov registry record
Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Immediate Release Tacrolimus to Slow Release Envarsus
A clinical trial, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- 30
- Enrollment target
NCT03703154 is a clinical trial that has completed, run by University of Kansas Medical Center. The registered enrollment target is 30 participants.
The verdict
NCT03703154 has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if conversion from immediate release tacrolimus to Envarsus improves cerebral blood flow, brain blood flow response to exercise, and cognition.
Interventions
- DRUG Tacrolimus
- DRUG Envarsus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-10-25 |
| Est. Completion | 2021-03-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03703154
The ClinicalTrials.gov registry entry for NCT03703154 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tacrolimus is the first listed.
NCT03703154 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03703154 about?
NCT03703154 is a clinical study titled "Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Immediate Release Tacrolimus to Slow Release Envarsus". The purpose of this study is to learn if conversion from immediate release tacrolimus to Envarsus improves cerebral blood flow, brain blood flow response to exercise, and cognition.
What is the current status of trial NCT03703154?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2018-10-25. Estimated completion is 2021-03-03.
What interventions are being tested in trial NCT03703154?
The interventions under investigation include: Tacrolimus (DRUG), Envarsus (DRUG).
Who is sponsoring clinical trial NCT03703154?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.